Blood thinners may prevent strokes in Moderate-Risk AF patients, trial investigates
NCT ID NCT04437654
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests whether direct oral anticoagulants (DOACs) like apixaban or rivaroxaban reduce the risk of stroke, major bleeding, or heart-related death in people with atrial fibrillation who have an intermediate stroke risk (CHA2DS2-VASc score of 1 in men or 2 in women). About 1,800 participants in South Korea are randomly assigned to receive a DOAC or no anticoagulant for two years. The goal is to see if the benefits of blood thinning outweigh the risks in this moderate-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apixaban or rivaroxaban (blood thinners)
- What this could lead to
- If it works, this could clarify whether blood thinners benefit people with atrial fibrillation who have a moderate stroke risk, potentially preventing strokes without causing excessive bleeding.
- What could go wrong
- This is a Phase 4 trial, so the drugs are already approved, but the benefit in this specific intermediate-risk group is unproven. There is a risk of major bleeding, and the open-label design may introduce bias.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION PATIENTS WITH INTERMEDIATE STROKE RISK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Cardiovascular Hospital Yonsei University
Seoul, South Korea